MARKET

JANX

JANX

Janux Therapeutics, Inc.
NASDAQ

Real-time Quotes | Nasdaq Last Sale

20.70
-2.17
-9.49%
After Hours: 20.70 0 0.00% 16:00 09/24 EDT
OPEN
22.73
PREV CLOSE
22.87
HIGH
24.07
LOW
20.48
VOLUME
115.09K
TURNOVER
--
52 WEEK HIGH
37.99
52 WEEK LOW
16.32
MARKET CAP
861.36M
P/E (TTM)
10.61
1D
5D
1M
3M
1Y
5Y
48 Biggest Movers From Friday
Gainers Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS) shares jumped 135.4% to settle at $5.32 on Friday. The stock possibly traded higher following favorable data results by AstraZeneca for patients with unresectable, stage 3 non-small cell lung cancer.
Benzinga · 5d ago
Insiders at Janux Therapeutics, Inc. (NASDAQ:JANX) snagged a bargain: a US$631k profit on a US$1m buy
Insiders who bought Janux Therapeutics, Inc. ( NASDAQ:JANX ) stock lover the last 12 months are probably not as...
Simply Wall St. · 09/12 14:40
BRIEF-Janux Therapeutics Appoints Ron Barrett And Alana Mcnulty To Board Of Directors
reuters.com · 09/09 20:36
Janux Therapeutics Appoints Ron Barrett, Ph.D., and Alana McNulty to Board of Directors
SAN DIEGO, September 09, 2021--Janux Therapeutics, Inc. (Nasdaq: JANX) (Janux), a biopharmaceutical company developing a broad pipeline of novel immunotherapies by applying its proprietary technology to its Tumor Activated T Cell Engager (TRACTr) and Tumor...
Business Wire · 09/09 20:01
Janux Therapeutics to Present Virtually at the H.C. Wainwright 23rd Annual Global Investor Conference
SAN DIEGO, September 07, 2021--Janux Therapeutics, Inc. (Nasdaq: JANX) (Janux), a biopharmaceutical company developing a broad pipeline of novel immunotherapies by applying its proprietary technology to its Tumor Activated T Cell Engager (TRACTr) and Tumor...
Business Wire · 09/07 20:01
Samsara BioCapital, LLC Buys Graphite Bio Inc, Centessa Pharmaceuticals PLC, Recursion ...
GuruFocus News · 08/24 22:38
Ra Capital Management, L.p. Buys Janux Therapeutics Inc, Vor Biopharma Inc, Aerovate ...
GuruFocus News · 08/24 17:38
5AM Venture Management, LLC Buys Vor Biopharma Inc, Impel NeuroPharma Inc, Janux Therapeutics ...
GuruFocus News · 08/23 07:26
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of JANX. Analyze the recent business situations of Janux Therapeutics, Inc. through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 4 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average JANX stock price target is 35.00 with a high estimate of 35.00 and a low estimate of 35.00.
EPS
Institutional Holdings
Institutions: 30
Institutional Holdings: 24.74M
% Owned: 59.46%
Shares Outstanding: 41.61M
TypeInstitutionsShares
Increased
0
0
New
30
24.74M
Decreased
0
0
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
-2.13%
Pharmaceuticals & Medical Research
-1.02%
Key Executives
President/Chief Executive Officer/Founder/Director/Primary Contact
David Campbell
Executive Officer
Andy Meyer
Other
Tommy Diraimondo
Other
Neil Gibson
Other
Marc Nasoff
Director
Ronald Barrett
Director
Alana Mcnulty
No Data
About JANX
Janux Therapeutics, Inc. is a biopharmaceutical company. The Company is engaged in developing therapeutics based on its Tumor Activated T Cell Engager (TRACTr) platform technology to treat patients suffering from cancer. Its focus is on developing a class of T cell engagers (TCEs). It is developing a broad pipeline with programs targeting prostate-specific membrane antigen (PSMA), epidermal growth factor receptor (EGFR), and trophoblast cell surface antigen 2 (TROP2). Its pipeline includes PSMA-TRACTr, EGFR-TRACTr and TROP2-TRACTr. The Company's PSMA-TRACTr is designed to target PSMA, a protein expressed in prostate cancer tumors and the vasculature of other tumors. Its EGFR-TRACTr is designed to target EGFR. TROP2-TRACTr is designed to target TROP2, a clinically validated anti-tumor target. The Company is also applying its technology to develop a Tumor Activated Immunomodulator (TRACIr) costimulatory bispecific product candidate against programmed death-ligand 1 (PD-L1) and CD28.

Webull offers kinds of Janux Therapeutics Inc stock information, including NASDAQ:JANX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, JANX stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading JANX stock methods without spending real money on the virtual paper trading platform.